ReviewNature reviews. Rheumatology2021
Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.
Review in Nature reviews. Rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis.BMC nephrology · 2024Pooled it
- Efficacy and safety of Danggui Niantong Decoction in patients with gout: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Effect of tea intake on genetic predisposition to gout and uric acid: a Mendelian randomization study.Frontiers in endocrinology · 2023Pooled it
- Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.Advances in therapy · 2026Trial
- Revisiting the Ethics of Urate-Lowering Therapy Clinical Trials for Gout Management.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Multiscale segmentation using hierarchical phase-contrast tomography and deep learning.PLoS computational biology · 2026Article
- Gout prevalence and management strategies among patients with moderate to advanced chronic kidney disease.Jornal brasileiro de nefrologia · 2026Article
- Association between serum urate, gout and chronic kidney disease: a scoping review of systematic reviews and meta-analyses.Journal of rheumatic diseases · 2025Review
- Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease.Gout, urate, and crystal deposition disease · 2025Article
- Gut bacteria degrade purines via the 2,8-dioxopurine pathway.Nature microbiology · 2025Article
- Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model.Rheumatology and therapy · 2025Article
- Quality Care Assessment in Gout.Current rheumatology reports · 2025Review
- Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review.Journal of nephrology · 2025Article
- Article
- Combination of sodium-glucose cotransporter type 2 inhibitors and urate-lowering therapy in people with gout from a specialist clinic: a retrospective, single-center observational study.Frontiers in medicine · 2025Article
- Editorial: Community series in advances in pathogenesis and therapies of gout, volume II.Frontiers in immunology · 2025Article
- Impaired pulmonary function increases the risk of gout: evidence from a large cohort study in the UK Biobank.BMC medicine · 2024Article
- Projected Health and Economic Burden of Comorbid Gout and Chronic Kidney Disease in a Virtual US Population: A Microsimulation Study.Rheumatology and therapy · 2024Article
- Article
- Single photon emission computed tomography/computed tomography imaging of gouty arthritis: A new voice.Journal of translational internal medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout and chronic kidney disease (CKD) frequently coexist, but quality evidence to guide gout management in people with CKD is lacking. Use of urate-lowering therapy (ULT) in the context of advanced CKD varies greatly, and professional bodies have issued conflicting recommendations regarding the treatment of gout in people with concomitant CKD. As a result, confusion exists among medical professionals about the appropriate management of people with gout and CKD. This Consensus Statement from the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) discusses the evidence and/or lack thereof for the management of gout in people with CKD and identifies key areas for research to address the challenges faced in the management of gout and CKD. These discussions, which address areas for research both in general as well as related to specific medications used to treat gout flares or as ULT, are supported by separately published G-CAN systematic literature reviews. This Consensus Statement is not intended as a guideline for the management of gout in CKD; rather, it analyses the available literature on the safety and efficacy of drugs used in gout management to identify important gaps in knowledge and associated areas for research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.